Regeneron says Phase 3 OPTIMA extension shows zero new HO lesions with Pasatru in adult FOP patients through week 84
Regeneron reported 84-week Phase 3 OPTIMA extension results for Pasatru in adults with fibrodysplasia ossificans progressiva, presented at ASBMR. Extension data showed sustained suppression of new abnormal bone growth, supporting longer-term disease control beyond the initial placebo-controlled period. Clinician-assess